A compound for use in the treatment of cancer, preferably neuroblastoma, T-cell lymphomas, urothelial or breast cancer, wherein said compound has the general formula III wherein n is an integer of 1 to 7, preferably 1 to 4, R 1, R 2, R 3, R 4, R 5, R 6 and R 7 are each independently selected from hydrogen, halogen, such as I, Cl, Br, F, NO 2, CN, SO 3, N(R 10) 2, O-X, S-X, NR 8 -X, -NR 10 C(=O)-X, S(=O)-X, S(=O) 2 -X, NHS(=O) 2 -X, C 1 -C 6 alkyl-X, C 2 -C 6 alkenyl-X, C 2 -C 6 alkynyl-X, C 1 -C 6 heteroalkyl-X, C 1 -C 6 fluoroalkyl-X, partially fluorinated C 1 -C 6 alkyl-X, C 1 -C 6 alkyl-O-X, C 1 -C 3 alkyl-O-C 1 -C 3 alkyl-X, C 1 -C 6 alkyl-NR 8 -X, C 1 -C 3 alkyl-NR 8 -C 1 -C 3 alkyl -X, C 1 -C 6 alkyl-C(=O)NR 8 -X, C 1 -C 3 alkyl-C(=O)NR 8 -C 1 -C 3 alkyl-X, C 1 -C 6 alkyl-NR 8 C(=O)-X, C 1 -C 3 alkyl-NR 8 C(=O)-C 1 -C 3 alkyl-X, C 1 -C 6 alkyl-S-X, C 1 -C 3 alkyl-S-C 1 -C 3 alkyl-X, C 1 -C 6 alkyl-S(=O)-X, C 1 -C 3 alkylS(=O)-C 1 -C 3 alkyl-X, C 1 -C 6 alkyl-S(=O) 2 -X, C 1 -C 3 alkyl-S(=O) 2 -C 1 -C 3 alkyl-X, C(=O)-X, C(=O)-NR 8 -X, C(=O)-C 1 -C 6 alkyl-X, substituted or unsubstituted C 2 -C 10 heterocycloalkyl, substituted or unsubstituted aryl, heteroaryl, Si 1 -Si 3 silyl-X, Si 2 -Si 4 siloxane-X; X is hydrogen, or a substituted or unsubstituted group selected from aryl, heteroaryl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 fluoroalkyl, partially fluorinated C 1 -C 6 alkyl, C 1 -C 3 alkylaminoC 1 -C 3 alkoxy, hydroxyC 1 -C 3 alkylaminoC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 2 alkyl, CN, NO 2, SO 3, CO 2 R 9, C(=O)R 9, S-R 9, S(=O)-R 9, S(=O) 2 -R 9, NR 10 C(=O)-R 9, C(=O)N(R 10) 2, S(=O) 2 N(R 10) 2, NR 10 S(=O) 2 -R 9, OC(=O)N(R 10) 2, NR 10 C(=O)O-R 9, -OC(=O)O-R 9, NHC(=O)NH-R 9, OC(=O)R 9, N(R 10) 2, C 1 -C 2 alkylN(R 10) 2, C 2 -C 6 alkyne, C 1 -C 6 heteroalkyl, C 3 -C 10 cycloalkyl, C 2 -C 10 heterocycloalkyl, Si 1 -Si 3 silyl, Si 2 -Si 4 siloxane; R 8 is selected from hydrogen, C 1 -C 6 alkyl, phenyl or benzyl; R 9 is a substituted or unsubstituted group selected from C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, partially fluorinated C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl; R 10 and R 11 are each independently selected from hydrogen, or a substituted or unsubstituted group selected from C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, partially fluorinated C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl; or a pharmaceutically accepted salt thereof. n is an integer of 1 to 7, preferably 1 to 4, R 1, R 2, R 3, R 4, R 5, R 6 and R 7 are each independently selected from hydrogen, halogen, such as I, Cl, Br, F, NO 2, CN, SO 3, N(R 10) 2, O-X, S-X, NR 8 -X, -NR 10 C(=O)-X, S(=O)-X, S(=O) 2 -X, NHS(=O) 2 -X, C 1 -C 6 alkyl-X, C 2 -C 6 alkenyl-X, C 2 -C 6 alkynyl-X, C 1 -C 6 heteroalkyl-X, C 1 -C 6 fluoroalkyl-X, partially fluorinated C 1 -C 6 alkyl-X, C 1 -C 6 alkyl-O-X, C 1 -C 3 alkyl-O-C 1 -C 3 alkyl-X, C 1 -C 6 alkyl-NR 8 -X, C 1 -C 3 alkyl-NR 8 -C 1 -C 3 alkyl -X, C 1 -C 6 alkyl-C(=O)NR 8 -X, C 1 -C 3 alkyl-C(=O)NR 8 -C 1 -C 3 alkyl-X, C 1 -C 6 alkyl-NR 8 C(=O)-X, C 1 -C 3 alkyl-NR 8 C(=O)-C 1 -C 3 alkyl-X, C 1 -C 6 alkyl-S-X, C 1 -C 3 alkyl-S-C 1 -C 3 alkyl-X, C 1 -C 6 alkyl-S(=O)-X, C 1 -C 3 alkylS(=O)-C 1 -C 3 alkyl-X, C 1 -C 6 alkyl-S(=O) 2 -X, C 1 -C 3 alkyl-S(=O) 2 -C 1 -C 3 alkyl-X, C(=O)-X, C(=O)-NR 8 -X, C(=O)-C 1 -C 6 alkyl-X, substituted or unsubstituted C 2 -C 10 heterocycloalkyl, substituted or unsubstituted aryl, heteroaryl, Si 1 -Si 3 silyl-X, Si 2 -Si 4 siloxane-X; X is hydrogen, or a substituted or unsubstituted group selected from aryl, heteroaryl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 fluoroalkyl, partially fluorinated C 1 -C 6 alkyl, C 1 -C 3 alkylaminoC 1 -C 3 alkoxy, hydroxyC 1 -C 3 alkylaminoC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 2 alkyl, CN, NO 2, SO 3, CO 2 R 9, C(=O)R 9, S-R 9, S(=O)-R 9, S(=O) 2 -R 9, NR 10 C(=O)-R 9, C(=O)N(R 10) 2, S(=O) 2 N(R 10) 2, NR 10 S(=O) 2 -R 9, OC(=O)N(R 10) 2, NR 10 C(=O)O-R 9, -OC(=O)O-R 9, NHC(=O)NH-R 9, OC(=O)R 9, N(R 10) 2, C 1 -C 2 alkylN(R 10) 2, C 2 -C 6 alkyne, C 1 -C 6 heteroalkyl, C 3 -C 10 cycloalkyl, C 2 -C 10 heterocycloalkyl, Si 1 -Si 3 silyl, Si 2 -Si 4 siloxane; R 8 is selected from hydrogen, C 1 -C 6 alkyl, phenyl or benzyl; R 9 is a substituted or unsubstituted group selected from C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, partially fluorinated C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl; R 10 and R 11 are each independently selected from hydrogen, or a substituted or unsubstituted group selected from C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, partially fluorinated C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl;